CN106620642A - Western medicine composition for treating hyperglycemia - Google Patents
Western medicine composition for treating hyperglycemia Download PDFInfo
- Publication number
- CN106620642A CN106620642A CN201611171697.4A CN201611171697A CN106620642A CN 106620642 A CN106620642 A CN 106620642A CN 201611171697 A CN201611171697 A CN 201611171697A CN 106620642 A CN106620642 A CN 106620642A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- hyperglycaemia
- medicine compound
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a western medicine composition for treating hyperglycemia. The western medicine composition comprises the following main raw materials in parts by weight: 8-20 parts of vitamin B6, 15-17 parts of gypenosides XLVI, 0.5-0.9 parts of paclitaxtide, 4-17 parts of 5-hydroxytryptamine, 18-25 parts of dehydro-evodiamine, 11-15 parts of Mulberrin G, 4-9 parts of wilforine, 7-12 parts of jervine and 5-16 parts of scutellarin methyl ester. According to the drug disclosed by the invention, the raw material ingredients are strictly selected according to the understanding mechanism of hyperglycemia, so as to achieve the purpose of comprehensive rehabilitation; the western medicine composition has the characteristics of taking effect quickly, being stable in effect and convenient to carry and take, and having no toxicity or side effect after long-time administration.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of Western medicine compound for treating hyperglycaemia.
Background technology
When medically blood sugar when on an empty stomach (in 8 hours sugar-free and any containing sugared food intake) being higher than normal range (NR) (on an empty stomach
Blood sugar normal value 4.0-6.1mmol/L) it is referred to as hyperglycaemia, if after the meal two hours blood glucoses are higher than 7.8mmol/L, it is also possible to referred to as
Hyperglycaemia.Diabetes are a kind of endocrine system diseases with carbohydrate metabolism disturbance as cardinal symptom, and pathogenesis is pancreas islet in patient's body
Plain hyposecretion or insulin receptor dysfunction, clinical manifestation is empty stomach or postprandial blood sugar rising, glycosuria and hyperlipidemia, its
The incidence of disease is just in the trend for rising year by year.Although hyperglycaemia is not a kind of disease, also not exclusively it is equal to diabetes, hyperglycaemia
There is inevitable inner link with diabetes, clinically hyperglycaemia easy induced Diabetic really, and suffer from hyperglycaemia for a long time
It is also possible to that eyes, kidney, blood vessel, heart, nerve etc. can be damaged.
Still lack the specific drug for the treatment of diabetes at present.The medicine of western medical treatment diabetes mainly includes orally-taken blood sugar reducing class medicine
Thing and insulin, oral hypoglycemic drug includes sulfonylureas, biguanides, prandial glucose regulator etc..Although the above medicine
Treatment to diabetes has certain curative effect, but its effect is not it is obvious that some drugs on patients also have poison in clinic
Side effect, the side effect of such as biguanides most serious is to cause lactic acidosis, and the death rate is 50% after generation, unsuitable long-term
Take.
The content of the invention
It is an object of the invention to provide a kind of Western medicine compound for treating hyperglycaemia, to solve above-mentioned background technology in carry
The problem for going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of Western medicine compound for treating hyperglycaemia, be according to the primary raw material of weight portion：Vitamin B6 8-20 parts, strand
The blue saponins X LVI 15-17 parts of stock, Japanese yew peptide 0.5-0.9 parts, serotonine 4-17 parts, dehydroevodiamine 18-25 parts, mulberry
Flavones G 11-15 parts, wilforine 4-9 parts, garlic Li Lu alkali 7-12 parts, scutellarin methyl esters 5-16 parts.
As further scheme of the invention：The Western medicine compound of the treatment hyperglycaemia, according to the main original of weight portion
Expect be：Vitamin B6 9-15 parts, gypenoside XLVI 15-17 parts, Japanese yew peptide 0.5-0.9 parts, serotonine 8-13 parts,
Dehydroevodiamine 21-23 parts, phellinus ketone G 11-15 parts, wilforine 4-9 parts, garlic Li Lu alkali 9-11 parts, scutellarin first
Ester 9-14 parts.
As further scheme of the invention：The Western medicine compound of the treatment hyperglycaemia, according to the main original of weight portion
Expect be：12 parts of vitamin B6,16 parts of gypenoside XLVI, 0.7 part of Japanese yew peptide, 11 parts of serotonine, dehydrogenation evodia rutaecarpa
22 parts of alkali, 13 parts of phellinus ketone G, 6 parts of wilforine, 10 parts of garlic Li Lu alkali, 12 parts of scutellarin methyl esters.
A kind of preparation method of the Western medicine compound for treating hyperglycaemia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh vitamin B6, gypenoside XLVI, Japanese yew peptide,
Serotonine, dehydroevodiamine, phellinus ketone G, wilforine, garlic Li Lu alkali, scutellarin methyl esters, sieve, and machinery is mixed
Addition ultra-pure water after even, in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing,
At 4-8 DEG C, packaging obtains final product the Western medicine compound for the treatment of hyperglycaemia to temperature control.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of hyperglycaemia, so as to reach comprehensive rehabilitation
Purpose, with rapid-action, effect it is stable, carry taking convenience, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of Western medicine compound for treating hyperglycaemia, be according to the primary raw material of weight portion：8 parts of vitamin B6, gynostemma pentaphylla
15 parts of saponins X LVI, 0.5 part of Japanese yew peptide, 4 parts of serotonine, 18 parts of dehydroevodiamine, 11 parts of phellinus ketone G, thunder godvine
4 parts of secondary alkali, 7 parts of garlic Li Lu alkali, 5 parts of scutellarin methyl esters.
A kind of preparation method of the Western medicine compound for treating hyperglycaemia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh vitamin B6, gypenoside XLVI, Japanese yew peptide,
Serotonine, dehydroevodiamine, phellinus ketone G, wilforine, garlic Li Lu alkali, scutellarin methyl esters, sieve, and machinery is mixed
Addition ultra-pure water after even, in placing pharmacy mixer, mixes 4min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 4 DEG C, packaging obtains final product the Western medicine compound for the treatment of hyperglycaemia for degree control.
Embodiment 2
A kind of Western medicine compound for treating hyperglycaemia, be according to the primary raw material of weight portion：9 parts of vitamin B6, gynostemma pentaphylla
15 parts of saponins X LVI, 0.5 part of Japanese yew peptide, 8 parts of serotonine, 21 parts of dehydroevodiamine, 11 parts of phellinus ketone G, thunder godvine
4 parts of secondary alkali, 9 parts of garlic Li Lu alkali, 9 parts of scutellarin methyl esters.
A kind of preparation method of the Western medicine compound for treating hyperglycaemia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh vitamin B6, gypenoside XLVI, Japanese yew peptide,
Serotonine, dehydroevodiamine, phellinus ketone G, wilforine, garlic Li Lu alkali, scutellarin methyl esters, sieve, and machinery is mixed
Addition ultra-pure water after even, in placing pharmacy mixer, mixes 4min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 4 DEG C, packaging obtains final product the Western medicine compound for the treatment of hyperglycaemia for degree control.
Embodiment 3
A kind of Western medicine compound for treating hyperglycaemia, be according to the primary raw material of weight portion：12 parts of vitamin B6, strand
16 parts of blue saponins X LVI, 0.7 part of Japanese yew peptide, 11 parts of serotonine, 22 parts of dehydroevodiamine, 13 parts of phellinus ketone G, Thunder God
Rattan time 6 parts of alkali, 10 parts of garlic Li Lu alkali, 12 parts of scutellarin methyl esters.
A kind of preparation method of the Western medicine compound for treating hyperglycaemia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh vitamin B6, gypenoside XLVI, Japanese yew peptide,
Serotonine, dehydroevodiamine, phellinus ketone G, wilforine, garlic Li Lu alkali, scutellarin methyl esters, sieve, and machinery is mixed
Addition ultra-pure water after even, in placing pharmacy mixer, mixes 6min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 6 DEG C, packaging obtains final product the Western medicine compound for the treatment of hyperglycaemia for degree control.
Embodiment 4
A kind of Western medicine compound for treating hyperglycaemia, be according to the primary raw material of weight portion：15 parts of vitamin B6, strand
17 parts of blue saponins X LVI, 0.9 part of Japanese yew peptide, 13 parts of serotonine, 23 parts of dehydroevodiamine, 15 parts of phellinus ketone G, Thunder God
Rattan time 9 parts of alkali, 11 parts of garlic Li Lu alkali, 14 parts of scutellarin methyl esters.
A kind of preparation method of the Western medicine compound for treating hyperglycaemia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh vitamin B6, gypenoside XLVI, Japanese yew peptide,
Serotonine, dehydroevodiamine, phellinus ketone G, wilforine, garlic Li Lu alkali, scutellarin methyl esters, sieve, and machinery is mixed
Addition ultra-pure water after even, in placing pharmacy mixer, mixes 8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 8 DEG C, packaging obtains final product the Western medicine compound for the treatment of hyperglycaemia for degree control.
Embodiment 5
A kind of Western medicine compound for treating hyperglycaemia, be according to the primary raw material of weight portion：20 parts of vitamin B6, strand
17 parts of blue saponins X LVI, 0.9 part of Japanese yew peptide, 17 parts of serotonine, 25 parts of dehydroevodiamine, 15 parts of phellinus ketone G, Thunder God
Rattan time 9 parts of alkali, 12 parts of garlic Li Lu alkali, 16 parts of scutellarin methyl esters.
A kind of preparation method of the Western medicine compound for treating hyperglycaemia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh vitamin B6, gypenoside XLVI, Japanese yew peptide,
Serotonine, dehydroevodiamine, phellinus ketone G, wilforine, garlic Li Lu alkali, scutellarin methyl esters, sieve, and machinery is mixed
Addition ultra-pure water after even, in placing pharmacy mixer, mixes 8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 8 DEG C, packaging obtains final product the Western medicine compound for the treatment of hyperglycaemia for degree control.
Pharmacology test
1st, acute toxicity test
With Western medicine compound obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, continuously give in 24h
Medicine 3 times, per minor tick 6h, is administered every time 300mg/kg doses, and daily accumulation medicine total amount reaches 900mg medicines/kg, equivalent to people
90 times of quantity.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, hair color light, its average body
Weight increases with the prolongation of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain,
Thymus gland, stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).As a result show：West of the invention
Drug composition is without acute toxic reaction.
2nd, long term toxicity test
With Western medicine compound obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, by Western medicine group of the present invention
Compound is divided into low dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 100,200,300mg medicines/kg/d,
10,20,30 times equivalent to clinical dosage.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematology
Mark, blood parameters without significantly impact, Systematic anatomy, organ coefficient and histopathological examination also no abnormal disease
Reason changes.It is discontinued 2 weeks and also has no substantially change.As a result show：Western medicine compound of the present invention does not find in long term toxicity test
Overt toxicity reacts and delayed toxicity reaction.It can be seen that, Western medicine compound non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical testing
The hyperglycemic patients that in June, 2015 accepts for medical treatment in December, 2015；Totally 200 patients, wherein, the male sex 100, women
100；Age 22-75 year, average age 42.6 years old；Course of disease 1-10, average 4.5 years.
The Western medicine compound of the preparation of the embodiment of the present invention 3 is given, is within 5 days a course for the treatment of (treatment two according to 100mg/kg/ days
The individual course for the treatment of) carry out symptom follow-up record；Clinical efficacy criterion is that (1) effective diabetic symptom and complication disappear substantially,
Hemorheology 5, fibrinolytic system 2 are improved, and fasting blood-glucose is less than 110mg/dl, and twenty-four-hour urine sugar is less than 5g or blood sugar
Drop-out value is more than 50% before glucose in urine is relatively treated；(2) effectively diabetic symptom and complication substantially mitigate, Hemorheology and fibrinolytic
4 or 4 improvement derived above of system, fasting blood-glucose is less than 150mg/dl, and twenty-four-hour urine sugar is less than 10g or blood sugar urinary sugar is relatively controlled
Drop-out value is more than 30% before treating；(3) invalid diabetic symptom and complication are not improved, or even aggravation.
Treatment results：200 patients, 162 recoveries from illness, 20 are effective, and 8 are effectively, 10 invalid, total effective rates
95.0%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity those skilled in the art should
Using specification as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. a kind of Western medicine compound for treating hyperglycaemia, it is characterised in that the primary raw material according to weight portion is：Vitamin B6
8-20 parts, gypenoside XLVI 15-17 parts, Japanese yew peptide 0.5-0.9 parts, serotonine 4-17 parts, dehydroevodiamine
18-25 parts, phellinus ketone G 11-15 parts, wilforine 4-9 parts, garlic Li Lu alkali 7-12 parts, scutellarin methyl esters 5-16 parts.
2. it is according to claim 1 treatment hyperglycaemia Western medicine compound, it is characterised in that the west of the treatment hyperglycaemia
Drug composition, be according to the primary raw material of weight portion：Vitamin B6 9-15 parts, gypenoside XLVI 15-17 parts, Japanese yew peptide
0.5-0.9 parts, serotonine 8-13 parts, dehydroevodiamine 21-23 parts, phellinus ketone G 11-15 parts, wilforine 4-9
Part, garlic Li Lu alkali 9-11 parts, scutellarin methyl esters 9-14 parts.
3. it is according to claim 1 and 2 treatment hyperglycaemia Western medicine compound, it is characterised in that the treatment hyperglycaemia
Western medicine compound, be according to the primary raw material of weight portion：12 parts of vitamin B6,16 parts of gypenoside XLVI, Japanese yew peptide
0.7 part, 11 parts of serotonine, 22 parts of dehydroevodiamine, 13 parts of phellinus ketone G, 6 parts of wilforine, garlic Li Lu alkali 10
Part, 12 parts of scutellarin methyl esters.
4. a kind of preparation method of the Western medicine compound of the treatment hyperglycaemia as described in claim 1-3 is arbitrary, it is characterised in that
Concretely comprise the following steps：
First, in pharmaceutical grade clean area, vitamin B6, gypenoside XLVI, Japanese yew peptide, 5- hydroxyls are weighed by above-mentioned metering ratio
Primary colours amine, dehydroevodiamine, phellinus ketone G, wilforine, garlic Li Lu alkali, scutellarin methyl esters, sieve, after machinery is mixed
Addition ultra-pure water, in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature drying, temperature after mixing
At 4-8 DEG C, packaging obtains final product the Western medicine compound for the treatment of hyperglycaemia for control.
5. it is according to claim 4 treatment hyperglycaemia Western medicine compound preparation method, it is characterised in that concrete steps
Middle mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171697.4A CN106620642A (en) | 2016-12-17 | 2016-12-17 | Western medicine composition for treating hyperglycemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171697.4A CN106620642A (en) | 2016-12-17 | 2016-12-17 | Western medicine composition for treating hyperglycemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106620642A true CN106620642A (en) | 2017-05-10 |
Family
ID=58823994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611171697.4A Pending CN106620642A (en) | 2016-12-17 | 2016-12-17 | Western medicine composition for treating hyperglycemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106620642A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375294A (en) * | 2017-08-04 | 2017-11-24 | 上海华堇生物技术有限责任公司 | The medicinal usage of dehydroevodiamine |
-
2016
- 2016-12-17 CN CN201611171697.4A patent/CN106620642A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375294A (en) * | 2017-08-04 | 2017-11-24 | 上海华堇生物技术有限责任公司 | The medicinal usage of dehydroevodiamine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7985848B2 (en) | Pharmaceutical composition for preventing and treating diabetes or glucose control abnormality comprising ginsenosides | |
| CN101716182A (en) | combined medicine containing metformin hydrochloride and vitamin b12 | |
| CN106620642A (en) | Western medicine composition for treating hyperglycemia | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN108261412A (en) | Purposes of the leonurine in insulin sensitizer is prepared | |
| CN106728768A (en) | It is a kind of to treat Chinese and western medicinal composition of hyperglycaemia and preparation method thereof | |
| CN101897698A (en) | Sugar-lowering drug composition containing vildagliptin and B vitamins and application thereof | |
| CN109248259A (en) | A kind of pueraria lobata extract tablet and preparation method thereof | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN110384709A (en) | Composition and its application containing phloridzin and 1-DNJ | |
| CN101036714B (en) | Medicinal composition for treating and/or preventing diabetes | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN103263405B (en) | Medicinal composition for treating diabetes, and its application | |
| CN104224872A (en) | Health product for regulating blood sugar and blood fat | |
| CN109432082B (en) | Pharmaceutical composition for preventing and treating chemical liver injury | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| CN103191170B (en) | Healthcare product for auxiliary treatment of type 2 diabetes, and preparation method thereof | |
| CN102000168B (en) | Medicament for reducing blood sugar | |
| CN107198692A (en) | Application of the Acankoreanogenia A in treatment diabetes medicament is prepared | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN106727615A (en) | A kind of Western medicine compound for treating the infection of the upper respiratory tract | |
| US10561167B2 (en) | Hypoglycemic composition and preparation method thereof | |
| CN104873837A (en) | Traditional Chinese medicine granular preparation and preparing method thereof | |
| CN104840938A (en) | Chinese patent medicine for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |